Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire to back companies working on RIPK1 inhibitors despite setbacks for GSK in ...

Biopharma happenings in Asia-Pacific including deals and partnerships, grants, preclinical data and other news in brief: Adagene, Beone Medicines, Biocytogen, Brii, Chugai, Conjugatebio, Gero, ...

In a report released yesterday, Kerry Holford from Berenberg Bank maintained a Hold rating on Novartis, with a price target of $108.00. The company’s shares closed yesterday at $122.94. According to ...

In a report released yesterday, Kerry Holford from Berenberg Bank maintained a Hold rating on Novartis AG, with a price target of CHF89.00. The company’s shares opened today at CHF97.91. According to ...

Reproducible translation of transcriptomics data has been hampered by the ubiquitous presence of batch effects. Statistical methods for managing batch effects were initially developed in the setting ...

Some of the most high-profile acquisitions in recent years have involved women-fronted biotechs. BioSpace reviews five of the most notable here.